{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:36:54Z","timestamp":1787168214521,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Calreticulin (\n                    <jats:italic>CALR<\/jats:italic>\n                    ) mutations are detected in around 20% of patients with primary and post-essential thrombocythemia myelofibrosis (MF). Regardless of driver mutations, patients with splenomegaly and symptoms are generally treated with\n                    <jats:italic>JAK2<\/jats:italic>\n                    -inhibitors, most commonly ruxolitinib. Recently, new therapies specifically targeting the\n                    <jats:italic>CALR<\/jats:italic>\n                    mutant clone have entered clinical investigation. To collect information on efficacy and safety of ruxolitinib in\n                    <jats:italic>CALR<\/jats:italic>\n                    -mutated patients, we report a sub-analysis of the \u201cRUX-MF\u201d (NCT06516406) study, comprising 135\n                    <jats:italic>CALR<\/jats:italic>\n                    -mutated and 786\n                    <jats:italic>JAK2<\/jats:italic>\n                    -mutated ruxolitinib-treated patients. Compared to\n                    <jats:italic>JAK2<\/jats:italic>\n                    -mutated patients,\n                    <jats:italic>CALR<\/jats:italic>\n                    -mutated patients started ruxolitinib with a more severe disease (higher peripheral blast counts, lower hemoglobin levels and worse marrow fibrosis) and after a longer median time from diagnosis (2.6 versus 0.7 years,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). At 6 months, spleen responses were numerically inferior in\n                    <jats:italic>CALR<\/jats:italic>\n                    -mutated patients, who also had significantly lower rates of symptom responses (56.1% versus 66.7%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04).\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06204-5","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T03:39:55Z","timestamp":1737344395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy"],"prefix":"10.1007","author":[{"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Branzanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Morsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Dedola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Benevolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Beggiato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novella","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tieghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Crugnola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Binotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cavazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Scalzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santino","family":"Caserta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Massimo","family":"Lemoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cilloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Elli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"issue":"16","key":"6204_CR1","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood.2022017423","volume":"141","author":"F Passamonti","year":"2023","unstructured":"Passamonti F, Mora B (2023) Myelofibrosis Blood 141(16):1954\u20131970","journal-title":"Myelofibrosis Blood"},{"issue":"1","key":"6204_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ajh.26751","volume":"98","author":"J Thiele","year":"2023","unstructured":"Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM et al (2023) The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol 98(1):166\u2013179","journal-title":"Am J Hematol"},{"issue":"7","key":"6204_CR3","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28(7):1472\u20131477","journal-title":"Leukemia"},{"issue":"25","key":"6204_CR4","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood.2019000622","volume":"134","author":"J How","year":"2019","unstructured":"How J, Hobbs GS, Mullally A (2019) Mutant calreticulin in myeloproliferative neoplasms. Blood 134(25):2242\u20132248","journal-title":"Blood"},{"issue":"5","key":"6204_CR5","doi-asserted-by":"publisher","first-page":"E128","DOI":"10.1002\/ajh.25065","volume":"93","author":"TL Lasho","year":"2018","unstructured":"Lasho TL, Finke CM, Tischer A, Pardanani A, Tefferi A (2018) Mayo CALR mutation type classification guide using alpha helix propensity. Am J Hematol 93(5):E128\u2013E129","journal-title":"Am J Hematol"},{"issue":"25","key":"6204_CR6","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379\u20132390","journal-title":"N Engl J Med"},{"issue":"10","key":"6204_CR7","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1038\/bcj.2015.90","volume":"5","author":"P Guglielmelli","year":"2015","unstructured":"Guglielmelli P, Rotunno G, Fanelli T, Pacilli A, Brogi G, Calabresi L et al (2015) Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis. Blood Cancer J 5(10):e360","journal-title":"Blood Cancer J"},{"issue":"11","key":"6204_CR8","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","volume":"18","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas J, Hoffman R (2012) Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res 18(11):3008\u20133014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6204_CR9","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/bjh.13644","volume":"173","author":"P Guglielmelli","year":"2016","unstructured":"Guglielmelli P, Rotunno G, Bogani C, Mannarelli C, Giunti L, Provenzano A et al (2016) Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis. Br J Haematol 173(6):938\u2013940","journal-title":"Br J Haematol"},{"issue":"6","key":"6204_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/cncr.32664","volume":"126","author":"F Palandri","year":"2020","unstructured":"Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G et al (2020) Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer 126(6):1243\u20131252","journal-title":"Cancer"},{"issue":"3","key":"6204_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","volume":"97","author":"AT Kuykendall","year":"2018","unstructured":"Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E et al (2018) Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol 97(3):435\u2013441","journal-title":"Ann Hematol"},{"issue":"1","key":"6204_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV et al (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1):1\u201314","journal-title":"J Hematol Oncol"},{"key":"6204_CR13","doi-asserted-by":"crossref","unstructured":"Kramer F, Mullally A (2024) Antibody targeting of mutant calreticulin in myeloproliferative neoplasms. J Cell Mol Med.;28(5)","DOI":"10.1111\/jcmm.17896"},{"issue":"4","key":"6204_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","volume":"6","author":"S Elf","year":"2016","unstructured":"Elf S, Abdelfattah NS, Chen E, Perales-Pat\u00f3n J, Rosen EA, Ko A et al (2016) Mutant calreticulin requires both its mutant C-terminus and the Thrombopoietin receptor for Oncogenic Transformation. Cancer Discov 6(4):368\u2013381","journal-title":"Cancer Discov"},{"issue":"Supplement 1","key":"6204_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood-2022-159435","volume":"140","author":"E Reis","year":"2022","unstructured":"Reis E, Buonpane R, Celik H, Marty C, Lei A, Jobe F et al (2022) Discovery of INCA033989, a monoclonal antibody that selectively antagonizes mutant calreticulin oncogenic function in myeloproliferative neoplasms (MPNs). Blood 140(Supplement 1):14\u201315","journal-title":"Blood"},{"issue":"20","key":"6204_CR16","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"8","key":"6204_CR17","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM et al (2013) Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122(8):1395\u20131398","journal-title":"Blood"},{"issue":"9","key":"6204_CR18","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703\u20131708","journal-title":"Blood"},{"issue":"12","key":"6204_CR19","first-page":"12","volume":"2017 31","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M et al (2017) A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 2017 31(12):12","journal-title":"Leukemia"},{"key":"6204_CR20","doi-asserted-by":"crossref","unstructured":"Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS et al (2012) 25:9 The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Modern Pathology 2012;25(9):1193\u2013202","DOI":"10.1038\/modpathol.2012.87"},{"issue":"4","key":"6204_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29(4):392\u2013397","journal-title":"J Clin Oncol"},{"issue":"17","key":"6204_CR22","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A et al (2018) MIPSS70\u2009+\u2009version 2.0: mutation and karyotype-enhanced International Prognostic Scoring System for primary myelofibrosis. J Clin Oncol 36(17):1769\u20131770","journal-title":"J Clin Oncol"},{"key":"6204_CR23","unstructured":"Cancer Institute N (2017) Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0"},{"issue":"8","key":"6204_CR24","first-page":"8","volume":"12","author":"G Coltro","year":"2022","unstructured":"Coltro G, Mannelli F, Loscocco GG, Mannarelli C, Rotunno G, Maccari C et al (2022) Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. Blood Cancer J 2022 12(8):8","journal-title":"Blood Cancer J 2022"},{"issue":"33","key":"6204_CR25","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S et al (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098\u20134103","journal-title":"J Clin Oncol"},{"key":"6204_CR26","doi-asserted-by":"crossref","unstructured":"Breccia M, Celant S, Palandri F, Passamonti F, Olimpieri PP, Summa V et al (2024) Oct The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: a prospective real-world study on AIFA monitoring registries. Br J Haematol","DOI":"10.1111\/bjh.19812"},{"issue":"45","key":"6204_CR27","doi-asserted-by":"publisher","first-page":"79073","DOI":"10.18632\/oncotarget.18674","volume":"8","author":"F Palandri","year":"2017","unstructured":"Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B et al (2017) Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget 8(45):79073\u201379086","journal-title":"Oncotarget"},{"key":"6204_CR28","doi-asserted-by":"crossref","unstructured":"Masarova L, Verstovsek S, Liu T, Rao S, Sajeev G, Fillbrunn M et al (2024) Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM. Future Oncol.;20(30)","DOI":"10.1080\/14796694.2024.2368450"},{"issue":"12","key":"6204_CR29","first-page":"1","volume":"30","author":"AT Gerds","year":"2024","unstructured":"Gerds AT, Tkacz J, Moore-Schiltz L, Schinkel J, Phiri K, Liu T et al (2024) Evaluating estimated health care resource utilization and costs in patients with myelofibrosis based on transfusion status and anemia severity: a retrospective analysis of the Medicare Fee-for-Service claims data. J Manag Care Spec Pharm 30(12):1\u201310","journal-title":"J Manag Care Spec Pharm"},{"key":"6204_CR30","doi-asserted-by":"crossref","unstructured":"Harrison CN, Mesa R, Talpaz M, Gupta V, Gerds AT, Perkins A et al (2024 Oct) Longitudinal Assessment of Transfusion Intensity in patients with JAK inhibitor-naive or -experienced myelofibrosis treated with Momelotinib. Clin Lymphoma Myeloma Leuk","DOI":"10.1016\/j.clml.2024.10.001"},{"key":"6204_CR31","doi-asserted-by":"crossref","unstructured":"Daskalopoulou C, Gorsh B, Dumi G, Deheshi S, Gwaltney C, Paty J et al (2024) Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study. Qual Life Res.;1\u201312","DOI":"10.1007\/s11136-024-03855-1"},{"issue":"6","key":"6204_CR32","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","volume":"6","author":"M Maffioli","year":"2022","unstructured":"Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC et al (2022) A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv 6(6):1855\u20131864","journal-title":"Blood Adv"},{"issue":"5","key":"6204_CR33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.15450","volume":"182","author":"E Cris\u00e0","year":"2018","unstructured":"Cris\u00e0 E, Cilloni D, Elli EM, Martinelli V, Palumbo GA, Pugliese N et al (2018) The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. Br J Haematol 182(5):701\u2013704","journal-title":"Br J Haematol"},{"issue":"4","key":"6204_CR34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/hon.3026","volume":"40","author":"S Qu","year":"2022","unstructured":"Qu S, Xu Z, Qin T, Li B, Pan L, Chen J et al (2022) Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: results of a pilot study. Hematol Oncol 40(4):787\u2013795","journal-title":"Hematol Oncol"},{"key":"6204_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.leukres.2017.06.005","volume":"60","author":"K Gowin","year":"2017","unstructured":"Gowin K, Kosiorek H, Dueck A, Mascarenhas J, Hoffman R, Reeder C et al (2017) Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leuk Res 60:31\u201335","journal-title":"Leuk Res"},{"issue":"2","key":"6204_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bjh.18057","volume":"197","author":"EM Elli","year":"2022","unstructured":"Elli EM, Di Veroli A, Bartoletti D, Iurlo A, Carmosino I, Benevolo G et al (2022) Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: the multicentre retrospective RUX-IOL study. Br J Haematol 197(2):190\u2013200","journal-title":"Br J Haematol"},{"issue":"4","key":"6204_CR37","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/ejh.13910","volume":"110","author":"E Inzoli","year":"2023","unstructured":"Inzoli E, Cris\u00e0 E, Pugliese N, Civettini I, Lanzarone G, Castelli A et al (2023) Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. Eur J Haematol 110(4):354\u2013361","journal-title":"Eur J Haematol"},{"issue":"7","key":"6204_CR38","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1080\/10428194.2022.2043304","volume":"63","author":"R Mesa","year":"2022","unstructured":"Mesa R, Oh ST, Gerds AT, Gupta V, Catalano J, Cervantes F et al (2022) Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leuk Lymphoma 63(7):1718\u20131722","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"6204_CR39","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A et al (2017) Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol 4(5):e225\u2013e236","journal-title":"Lancet Haematol"},{"key":"6204_CR40","doi-asserted-by":"publisher","first-page":"103862","DOI":"10.1016\/j.critrevonc.2022.103862","volume":"180","author":"F Passamonti","year":"2022","unstructured":"Passamonti F, Harrison CN, Mesa RA, Kiladjian JJ, Vannucchi AM, Verstovsek S (2022) Anemia in myelofibrosis: current and emerging treatment options. Crit Rev Oncol Hematol 180:103862","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"6204_CR41","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/cncr.34707","volume":"129","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Kiladjian JJ, Vannucchi AM, Mesa RA, Squier P, Hamer-Maansson JE et al (2023) Early intervention in myelofibrosis and impact on outcomes: a pooled analysis of the COMFORT-I and COMFORT-II studies. Cancer 129(11):1681\u20131690","journal-title":"Cancer"},{"key":"6204_CR42","doi-asserted-by":"crossref","unstructured":"Palandri F, Palumbo GA, Benevolo G, Iurlo A, Elli EM, Abruzzese E et al (2024) Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer.;130(8)","DOI":"10.1002\/cncr.35156"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06204-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06204-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06204-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T15:10:57Z","timestamp":1737385857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06204-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":42,"alternative-id":["6204"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06204-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"29 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francesca Palandri reports consultancy and honoraria from Novartis, BMS, AOP, Sierra Oncology, Incyte, Telios, Abbvie, Constellation-Morphosys, Sobi and GSK. Giulia Benevolo reports honoraria from Novartis, Janssen, Amgen, Takeda, and BMS. Massimo Breccia reports honoraria from Novartis, BMS, Pfizer, Incyte and is the Editor-in Chief of Annals of Hematology. Massimiliano Bonifacio reports honoraria from Novartis, BMS, Pfizer, and Incyte. Monica Crugnola reports honoraria from Novartis and Amgen. Gianni Binotto reports honoraria from Novartis, Incyte, BMS-Celgene, and Pfizer. Roberto M. Lemoli reports honoraria from Jazz, Pfizer, AbbVie, BMS, Sanofi, and StemLine. Fabrizio Pane reports honoraria from Incyte, Novartis, Jazz, BMS-Celgene, Amgen, and Gilead. Giuseppe A. Palumbo reports consultancy and honoraria from Abbvie, AOP, AstraZeneca, BMS, Incyte, GSK, Morphosys, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}